Background: Few studies have assessed how mobile messenger apps affect COVID-19 vaccine hesitancy. We created a COVID-19 vaccine information chatbot in a popular messenger app in Japan to answer commonly asked questions. Methods: LINE is the most popular messenger app in Japan. Corowa-kun, a free chatbot, was created in LINE on February 6, 2021. Corowa-kun provides instant, automated answers to frequently asked COVID-19 vaccine questions. In addition, a cross-sectional survey assessing COVID-19 vaccine hesitancy was conducted via Corowa-kun during April 5 to 12, 2021. Results: A total of 59,676 persons used Corowa-kun during February to April 2021. Of them, 10,192 users (17%) participated in the survey. Median age was 55 years (range 16 to 97), and most were female (74%). Intention to receive a COVID-19 vaccine increased from 59% to 80% after using Corowa-kun (p < 0.01). Overall, 20% remained hesitant: 16% (1,675) were unsure, and 4% (364) did not intend to be vaccinated. Factors associated with vaccine hesitancy were: age 16 to 34 (odds ratio [OR] = 3.7, 95% confidential interval [CI]: 3.0-4.6, compared to age ≥ 65), female sex (OR = 2.4, Cl: 2.1-2.8), and history of another vaccine side-effect (OR = 2.5, Cl: 2.2-2.9). Being a physician (OR = 0.2, Cl: 0.1-0.4) and having received a flu vaccine the prior season (OR = 0.4, Cl: 0.3-0.4) were protective. Conclusions: Corowa-kun reduced vaccine hesitancy by providing COVID-19 vaccine information in a messenger app. Mobile messenger apps could be leveraged to increase COVID-19 vaccine acceptance.
Background Japan has one of the highest vaccine hesitancy rates in the world. According to a previous study, less than 30% of people strongly agreed that vaccines were safe, important, or effective. We created a COVID-19 vaccine information chatbot in a popular messenger app in Japan to answer COVID-19 vaccine frequently asked questions (FAQs) via text messages. We assessed the impact of chatbot text messages on COVID-19 vaccine hesitancy by conducting a cross-sectional survey among chatbot users. Methods LINE is the most popular messenger app in Japan; about 86 million people in Japan (roughly two-thirds of the population) use this messenger app. Corowa-kun, a free chatbot, was created in LINE on February 6, 2021. Corowa-kun provides instant, automated answers to frequently asked COVID-19 vaccine questions. A cross-sectional survey assessing COVID-19 vaccine hesitancy was conducted via Corowa-kun during April 5 to 12, 2021. We included persons ages 16 years old and older who had not received a COVID-19 vaccine. The survey was written in Japanese and consisted of 21 questions. Corowa-kun’s Consultation Room Corowa-kun is the mascot of an online chatbot. This chatbot in LINE is used to answer COVID-19 vaccine frequently asked questions (FAQs) via text messages. As of May 10th, 70 FAQs are available. Results A total of 59,676 persons used Corowa-kun during February to April 2021. The most commonly accessed message categories were: “I have (select comorbidity), can I get a COVID-19 vaccine?” (23%); followed by questions on adverse reactions (22%) and how the vaccine works (20%). 10,192 users (17%) participated in the survey. Median age was 55 years (range 16 to 97), and most were female (74%). Intention to receive a COVID-19 vaccine increased from 59% to 80% after using Corowa-kun (p < 0.01). Overall, 20% remained hesitant: 16% (1,675) were unsure, and 4% (364) did not intend to be vaccinated. Factors associated with vaccine hesitancy were: age 16 to 34 (odds ratio [OR] = 3.7, 95% confidential interval [CI]: 3.0–4.6, compared to age ≥65), female sex (OR = 2.4, Cl: 2.1–2.8), and history of another vaccine side-effect (OR = 2.5, Cl: 2.2–2.9). Being a physician (OR = 0.2, Cl: 0.1-0.4) and having received a flu vaccine the prior season (OR = 0.4, Cl: 0.3-0.4) were protective. COVID-19 vaccine acceptance increased and hesitancy decreased after using Corowa-kun, Japan, 2021 (n=10,192) *There was a statistically significant difference in responses between before and after using Corowa-kun (p < 0.01, Chi-square test). Univariable logistic regression models of factors associated with COVID-19 vaccine hesitancy, Japan, 2021 (n=10,192) Ref: reference NA: Logistic regression was not performed due to too small number (n≤3) Conclusion Corowa-kun reduced vaccine hesitancy by providing COVID-19 vaccine information in a messenger app. Mobile messenger apps could be leveraged to increase COVID-19 vaccine acceptance. Disclosures All Authors: No reported disclosures
Background Little is known about how social media platforms can be used to increase COVID-19 vaccine intent. We aimed to investigate the effect of social media-based interventions on vaccine hesitancy in Japan. Methods We conducted a three-arm randomized controlled trial between 5 November 2021 and 9 January 2022. Japanese aged 20 or above who had not received any COVID-19 vaccine and did not intend to be vaccinated were randomly assigned to one of the following three groups: (i) a control group (with no intervention), (ii) a group with a free chatbot in a popular messenger app called ‘LINE,’ which provided general information on COVID-19 vaccines and (iii) a group with free webinars where healthcare professionals interactively provided participants with the information on COVID-19 vaccines. The vaccine intention (VI) and three pre-defined Vaccine Confidence Index (VCI), including the importance, safety, and effectiveness of COVID-19 vaccines, were compared. Results 1,158 persons were included, and the baseline characteristics and demographics were balanced across three groups (Table 1). Among 386 persons assigned to the chatbot group, 231 (59.8%) accessed the chatbot and answered the post-survey. The post-survey revealed no significant difference in VI or VCI between the chatbot group and the control group (Table 2). Among 386 persons assigned to the webinar group, 207 (53.6%) attended webinars and answered the post-survey. The post-survey revealed no difference in VI between the webinar group and the control group. However, the VCI for the importance and the effectiveness significantly increased in the webinar group. There was no difference in VCI for the safety. VCI for the importance and the effectiveness in the control group decreased without any intervention during the study period. Vaccine intention and confidence after interventions Table 1Table 2 Conclusion While this study demonstrated that neither the chatbot nor the webinar changed VI, VCI for the importance and the effectiveness significantly increased with the webinar intervention. Interactive webinars with live Q and A provided by professionals may have a role in increasing COVID-19 vaccine confidence. Given the degree of vaccine hesitancy worsened over time in the control group, timely intervention is required. Disclosures All Authors: No reported disclosures.
IntroductionWe investigated the effect of social media-based interventions on COVID-19 vaccine intention (VI) and confidence in Japan.MethodsWe conducted a three-arm randomised controlled trial between 5 November 2021 and 9 January 2022 during a low incidence (<1000/day) of COVID-19 in Japan in the midst of the second and the third waves. Japanese citizens aged ≥20 who had not received any COVID-19 vaccine and did not intend to be vaccinated were randomly assigned to one of the following three groups: (1) a control group, (2) a group using a mobile app chatbot providing information on COVID-19 vaccines and (3) a group using interactive webinars with health professionals. VI and predefined Vaccine Confidence Index (VCI) measuring confidence in the importance, safety and effectiveness were compared before and after the interventions under intention-to-treat principle. Logistic regression models were used to investigate the effect of each intervention on postintervention VI and changes of VCI compared with control.ResultsAmong 386 participants in each group, 359 (93.0%), 231 (59.8%) and 207 (53.6%) completed the postsurvey for the control, chatbot and webinar groups, respectively. The average duration between the intervention and the postsurvey was 32 days in chatbot group and 27 days in webinar group. VI increased from 0% to 18.5% (95% CI 14.5%, 22.5%) in control group, 15.4% (95% CI 10.8%, 20.1%) in chatbot group and 19.7% (95% CI 14.5%, 24.9%) in webinar group without significant difference (OR for improvement=0.8 (95% CI 0.5, 1.3), p=0.33 between chatbot and control, OR=1.1 (95% CI 0.7, 1.6), p=0.73 between webinar and control). VCI change tended to be larger in chatbot group compared with control group without significant difference (3.3% vs −2.5% in importance, OR for improvement=1.3 (95% CI 0.9, 2.0), p=0.18; 2.5% vs 1.9% in safety, OR=1.1 (95% CI 0.7, 1.9), p=0.62; −2.4% vs −7.6% in effectiveness, OR=1.4 (95% CI 0.9, 2.1), p=0.09). Improvement in VCI was larger in webinar group compared with control group for importance (7.8% vs −2.5%, OR=1.8 (95% CI 1.2, 2.8), p<0.01), effectiveness (6.4% vs −7.6%, OR=2.2 (95% CI 1.4, 3.4), p<0.01) and safety (6.0% vs 1.9%, OR=1.6 (95% CI 1.0, 2.6), p=0.08).ConclusionThis study demonstrated that neither the chatbot nor the webinar changed VI importantly compared with control. Interactive webinars could be an effective tool to change vaccine confidence. Further study is needed to identify risk factors associated with decreased vaccine confidence and investigate what intervention can increase VI and vaccine confidence for COVID-19 vaccines.Trial registration numberUMIN000045747.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.